Cinnarizine has an atypical antipsychotic profile in animal models of psychosis
- 1 July 2005
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 19 (4) , 342-346
Abstract
Cinnarizine, a drug known as a calcium channel blocker, is currently used for the treatment of migraine and vertigo. Induction of extrapyramidal signs by cinnarizine has been reported in the elderly, which is related to its moderate antagonistic properties at dopamine D2 receptors, resembling the mechanism of action of most antipsychotic drugs. Despite this effect, cinnarizine has never been tested as a putative antipsychotic drug. Here we evaluate the potential effect of cinnarizine in two pharmacological models of psychosis, namely amphetamine- and MK-801-induced hyperlocomotion, as well as its ability to induce catalepsy. Cinnarizine significantly counteracted MK-801 (0.25mg/kg) and amphetamine (5mg/kg) locomotor effects at doses as low as 20mg/kg, having no incremental effect at 60 or 180mg/kg. Regarding side-effects, cinnarizine induced no catalepsy in mice at the effective dose of 20mg/kg, inducing only mild catalepsy at the doses of 60 and 180mg/kg. Based on these results and on the antagonist effect of cinnarizine on dopamine D2 receptors, we suggest that it has a potential antipsychotic effect with an atypical profile that should be evaluated clinically.Keywords
This publication has 25 references indexed in Scilit:
- Animal behavior models of the mechanisms underlying antipsychotic atypicalityProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
- Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-d-aspartate receptor antagonist MK-801 in micePsychopharmacology, 2003
- Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicityMolecular Psychiatry, 2002
- Attenuation of the Neuropsychiatric Effects of Ketamine With LamotrigineArchives of General Psychiatry, 2000
- Radioreceptor Binding Profile of the Atypical Antipsychotic OlanzapineNeuropsychopharmacology, 1996
- D2 Receptor Blockade by Flunarizine and Cinnarizine Explains Extrapyramidal Side Effects. A SPECT StudyJournal of Cerebral Blood Flow & Metabolism, 1995
- Extrapyramidal Symptoms Associated with Calcium-Channel BlockersAnnals of Pharmacotherapy, 1995
- The Ability of Diphenylpiperazines to Prevent Neuronal Death in Dorsal Root Ganglion Neurons In Vitro After Nerve Growth Factor Deprivation and In Vivo After AxotomyJournal of Neurochemistry, 1994
- Cinnarizine-Induced Parkinsonism in PrimatesClinical Neuropharmacology, 1992
- Aggravation of Parkinson's disease by cinnarizine.Journal of Neurology, Neurosurgery & Psychiatry, 1988